Intec Pharma Ltd (NASDAQ:NTEC) saw a significant decrease in short interest in August. As of August 31st, there was short interest totalling 3,000,000 shares, a decrease of 27.2% from the August 15th total of 4,120,000 shares. Based on an average daily volume of 7,680,000 shares, the days-to-cover ratio is currently 0.4 days.

Shares of Intec Pharma stock traded down $0.01 during trading on Wednesday, hitting $0.28. The stock had a trading volume of 116,338 shares, compared to its average volume of 6,119,656. Intec Pharma has a 12 month low of $0.13 and a 12 month high of $1.56. The firm’s fifty day simple moving average is $0.34 and its 200-day simple moving average is $0.29. The stock has a market cap of $20.70 million, a PE ratio of -0.31 and a beta of 0.77.

Intec Pharma (NASDAQ:NTEC) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported ($0.05) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.05). Analysts forecast that Intec Pharma will post -0.21 earnings per share for the current year.

A number of hedge funds have recently added to or reduced their stakes in NTEC. Two Sigma Advisers LP boosted its stake in shares of Intec Pharma by 326.1% during the second quarter. Two Sigma Advisers LP now owns 88,200 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 67,500 shares during the period. Russell Investments Group Ltd. bought a new position in Intec Pharma in the 2nd quarter worth about $29,000. Integrated Wealth Concepts LLC purchased a new position in shares of Intec Pharma during the second quarter worth approximately $117,000. Harel Insurance Investments & Financial Services Ltd. raised its stake in shares of Intec Pharma by 61,948.1% during the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 367,325 shares of the biotechnology company’s stock valued at $104,000 after acquiring an additional 366,733 shares in the last quarter. Finally, Phoenix Holdings Ltd. increased its stake in shares of Intec Pharma by 315.9% during the first quarter. Phoenix Holdings Ltd. now owns 600,706 shares of the biotechnology company’s stock valued at $112,000 after buying an additional 456,255 shares during the period. Institutional investors and hedge funds own 10.00% of the company’s stock.

A number of equities analysts have commented on the stock. HC Wainwright reissued a “neutral” rating on shares of Intec Pharma in a research note on Monday, August 17th. Zacks Investment Research raised shares of Intec Pharma from a “sell” rating to a “hold” rating in a report on Thursday, July 16th. Finally, Maxim Group reissued a “hold” rating on shares of Intec Pharma in a research note on Thursday, August 6th. Five analysts have rated the stock with a hold rating and one has given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $0.63.

About Intec Pharma

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.

Further Reading: Return on Investment (ROI) Defined, Explained

Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.